Pfizer Reports First-Quarter 2009 Results
- Details
- Category: Pfizer
Pfizer Inc (NYSE: PFE) has reported financial results for first-quarter 2009. Revenues were $10.9 billion, a decrease of 8% compared with the year-ago quarter. Foreign exchange unfavorably impacted revenues by approximately $640 million or 5%. For first-quarter 2009, U.S. revenues were $5.0 billion, a decrease of 10% compared with the year-ago quarter.
Q1/2009: Merck Revenues Remain Stable at € 1.9 Billion
- Details
- Category: Merck Group
All in all, the Merck Group performed solidly during the first quarter of 2009. However, Merck is not an island. The recession is affecting the company's results, mainly in the Chemicals business sector. In addition, this year's first quarter is compared to a very strong first quarter in 2008.
Lilly Granted Preliminary Injunction to Prevent Launch of Generic Raloxifene
- Details
- Category: Eli Lilly and Company
Eli Lilly and Company (NYSE: LLY) announced that the U.S. District Court for the Southern District of Indiana has issued a preliminary injunction to prevent the launch of a generic version of Lilly's medicine Evista(R) (raloxifene HCl tablets) by Teva Pharmaceuticals until the Court renders its final ruling.
Pfizer And University College London Announce Collaboration To Advance Development Of Stem Cell-Base
- Details
- Category: Pfizer
Pfizer Regenerative Medicine today announced that it has entered into a collaboration and license agreement with University College London focused on gaining better understanding into how to develop stem cell-based therapies for certain ophthalmic conditions. The Pfizer/UCL collaboration brings together the pioneering work of university researchers in the field of cell-based therapies and Pfizer's expertise in the design and delivery of therapeutics.
Amgen's First Quarter 2009 Adjusted Earnings Per Share Decreased 4 Percent to $1.08
- Details
- Category: Amgen
Amgen (Nasdaq: AMGN) reported adjusted earnings per share (EPS) of $1.08 for the first quarter of 2009, a decrease of 4 percent compared to $1.12 for the first quarter of 2008. Adjusted net income decreased 8 percent to $1,120 million in the first quarter of 2009 compared to $1,218 million in the first quarter of 2008.
Pfizer and Medicines for Malaria Venture Advancing International Research Efforts
- Details
- Category: Pfizer
Pfizer Inc and Medicines for Malaria Venture (MVV) have signed an agreement that is designed to facilitate advancements in the battle against malaria, a disease that afflicts vulnerable populations in the developing world each year. Under the agreement, MMV will have access to the Pfizer library of novel chemical entities, in order to screen it for compounds that have the potential to be developed into new treatments for malaria.
Roche strongly outperforms market in first quarter
- Details
- Category: Roche
The Roche Group recorded total sales of 11.6 billion Swiss francs in the first quarter of 2009, an increase of 8% in local currencies (7% in Swiss francs; -1% in US dollars)1 compared with the year-earlier period. Growth was driven mainly by continued strong sales of key products in the Group's oncology, virology, ophthalmology and inflammation portfolios, and of Roche Diagnostics' immunoassay systems.
More Pharma News ...
- OTC weight loss aid is available in pharmacies across Europe
- Sanofi-aventis to acquire BiPar Sciences, a US biopharmaceutical company
- Abbott Reports 16 Percent Earnings Growth in First Quarter
- Roche Diabetes Care supports "Changing Diabetes in Children"
- FDA Advisory Committee Recommendation on Seroquel XR Supplemental New Drug Applications
- Genzyme to acquire the worldwide rights to Campath® (alemtuzumab) from Bayer HealthCare
- The First Pharmaceutical Company for Protection of Human Rights in Clinical Research